D
IRECTORS
C
ONTINUING
IN
O
FFICE
U
NTIL
THE
2020 A
NNUAL
M
EETING
Susan M. Molineaux, Ph.D.
Dr. Molineaux, age 65,
has served as our President, Chief Executive Officer and as a member of our board of directors since she
co-founded
Calithera in March 2010. Dr. Molineaux
co-founded
Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005, Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific
Officer from February 2009 until Proteolixs acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From
1999 to 2000, she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999, she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From
1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux currently serves as a member of the board of directors of Geron Corporation, Theravance Biopharma, Inc. and Smith College, and is a Scientific
Advisor for Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.
We believe Dr. Molineauxs experience on our board of directors and as our Chief Executive Officer, as well as her experience in our industry
qualifies her to serve on our board of directors.
Blake Wise.
Mr. Wise, age 48, has served as a member of our board of directors since
September 2017. Since January 2018, Mr. Wise has served as Chief Executive Officer and a member of the board of directors of Achaogen, a biopharmaceutical company developing innovative antibacterials. Mr. Wise joined Achaogen as Chief
Operating Officer in 2015 and, in February 2017, he was also appointed President. Prior to joining Achaogen, Mr. Wise served as Vice President, Cross BioOncology at Genentech, where he led cross-portfolio oncology initiatives, including key
account management, marketing, managed markets, companion diagnostics, pipeline commercialization, and long-term oncology strategy. Mr. Wise also held several other leadership positions at Genentech including Senior Director, Franchise Head and
Life Cycle Leader of the Lytics franchise and as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology, and Interactive Marketing Director. Prior to joining Genentech, Mr. Wise worked in consumer marketing,
e-commerce
and online marketing in leadership positions at Gap, Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of
Business Administration degree from University of California, Berkeley, Haas School of Business.
We believe Mr. Wises experience in the
biotechnology industry qualifies him to serve on our board of directors.
H. Ward Wolff.
Mr. Wolff, age 70, has served as a member of our
board of directors since December 2014. Mr. Wolff served as Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc. from 2007 until his retirement in March 2017. Prior to Sangamo, Mr. Wolff was with Nuvelo, Inc.,
where he served as Senior Vice President, Finance and Chief Financial Officer until its restructuring in August 2007. Prior to that, he was Chief Financial Officer and Senior Vice President, Finance, of Abgenix, Inc. until April 2006 when Abgenix
merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and CFO of DoubleTwist, Inc., a life sciences
company integrating genomic information and bioinformatics analysis tools. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including Senior Audit Manager. Mr. Wolff is a member of
the board of directors of Portola Pharmaceuticals, Inc. and Sunesis Pharmaceuticals, Inc. From June 2006 until his appointment to Sangamos management team he was a member of Sangamos Board of Directors, serving as Chairman of the Audit
Committee. Mr. Wolff received a B.A. degree in Economics from the University of California at Berkeley and an M.B.A. degree from Harvard Business School.
We believe Mr. Wolffs extensive financial experience and experience in the biotechnology industry qualifies him to serve on our board of directors.
8